title: Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.
abstract: We performed a retrospective population-based study using the SEER database to assess survival trends in CBF-AML between 2000 and 2010. Median OS increased from 16 months in 2000-2002 to 25 months in 2006-2008 (P=0.002). The 3-year OS rate for patients with inv(16) was 57.3%, but in t(8;21) was only 35.5%. Patients aged 75-84 had worse survival than patients aged 15-44 (HR 5.61, P=0.0002). Black race was associated with higher mortality (HR 1.50, P=0.03). Compared to clinical trial outcomes, CBF-AML survival is poorer in the general population, particularly among African Americans and the elderly, and in t(8;21) compared to inv(16) AML.
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States; Dana Farber Cancer Institute, Boston, MA, United States.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Brunner
authors.affiliation: Dana Farber Cancer Institute, Boston, MA, United States.
authors.forename: Traci M
authors.initials: TM
authors.lastname: Blonquist
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.
authors.forename: Hossein
authors.initials: H
authors.lastname: Sadrzadeh
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Perry
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.
authors.forename: Eyal C
authors.initials: EC
authors.lastname: Attar
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.
authors.forename: Philip C
authors.initials: PC
authors.lastname: Amrein
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.
authors.forename: Karen K
authors.initials: KK
authors.lastname: Ballen
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.
authors.forename: Yi-Bin
authors.initials: YB
authors.lastname: Chen
authors.affiliation: Dana Farber Cancer Institute, Boston, MA, United States.
authors.forename: Donna S
authors.initials: DS
authors.lastname: Neuberg
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States. Electronic address: afathi@partners.org.
authors.forename: Amir T
authors.initials: AT
authors.lastname: Fathi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D050660:Core Binding Factors / Q000378:metabolism*; D016208:Databases, Factual; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality*; D008875:Middle Aged; D012189:Retrospective Studies; D018426:SEER Program; D014178:Translocation, Genetic
chemical_list: D050660:Core Binding Factors
keywords: Acute myeloid leukemia; Core binding factors; Health status disparities; Population surveillance; Survival